US OptionsDetailed Quotes

STOK250117C10000

Watchlist

0.50
-0.92-64.79%

15min DelayClose Jan 7 16:00 ET

1.42High0.50Low

Stoke Therapeutics Stock Discussion

Trytosaveabit

Dec 4, 2024 06:03

News

$Stoke Therapeutics (STOK.US)$ Reuters· 2 mins ago
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

TrendTrader

Jul 26, 2024 14:38

Looking for 16, 16.6 and 17

$Stoke Therapeutics (STOK.US)$

Trytosaveabit

Mar 28, 2024 03:38

Impressed they made it this high price

$Stoke Therapeutics (STOK.US)$ Stoke Therapeutics Prices Upsized $125M Public Offering Of 5,555,557 Common Shares At $13.50/Share

Tao Lao Zoa

Mar 27, 2024 13:20

$Stoke Therapeutics (STOK.US)$ BUYERS MAKE 💰💰💰💰🤩🤩💰💰💰 SELL ALL AND NEVER BUY BACK NHAO NHAO 😍😍😍

PaulG

Mar 27, 2024 11:58

$Stoke Therapeutics (STOK.US)$ long at 12.50

Trytosaveabit

Mar 27, 2024 11:06

Hmm!

$Stoke Therapeutics (STOK.US)$ im liking a lot! i just wish they woulda attached a darn price to that offering! I mean 18 dollars great! WooHoo even! But if it ends up being 7/8! look out below! Hehehe

Deutsche Trader

Mar 26, 2024 23:51

$Stoke Therapeutics (STOK.US)$ AH went green after company announces stock offering. offering must be higher than current price. solid company here. PT 15-20 IMO

Trytosaveabit

Mar 26, 2024 15:29

Hmm!

$Stoke Therapeutics (STOK.US)$ Wow! So far it hasnt done the typical im dopping 25/40% when the offering comes out! Color me impressed! hehehe

Trytosaveabit

Mar 26, 2024 15:11

And the warning of be careful come to fruition! Hehehe

$Stoke Therapeutics (STOK.US)$ Stoke Therapeutics Announces Proposed Public Offering Of Up To $75M Of Common Stock

Stock Region

Mar 26, 2024 13:12

Therapeutics Company Beats Analyst Consensus Estimates

Stoke Therapeutics: A Glimpse into the Future of RNA-Based Medicine.
In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addres...

No comment yet